CANDEL THERAPEUTICS, INC. Shareholders' Equity
CANDEL THERAPEUTICS, INC. (CADL) had Shareholders' Equity of $126.13 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $126.13M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $138.03M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $51.92M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $80.12M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $126.13M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $138.03M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $51.92M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $80.12M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $90.21M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $74.67M 10-Q · filed 2026-08-13 |
| 2024-12-31 | $66.33M 10-Q · filed 2026-08-13 |
| 2024-09-30 | -$15.26M 10-Q · filed 2025-11-13 |
| 2024-06-30 | -$9.97M 10-Q · filed 2025-11-13 |
| 2024-03-31 | $5.98M 10-Q · filed 2025-08-14 |
| 2023-12-31 | $12.74M 10-K · filed 2026-03-12 |
| 2023-09-30 | $23.02M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $30.77M 10-Q · filed 2024-11-14 |
| 2023-03-31 | $39.65M 10-Q · filed 2024-08-13 |
| 2022-12-31 | $47.71M 10-K · filed 2025-03-13 |
| 2022-09-30 | $52.13M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $60.07M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $63.76M 10-Q · filed 2023-08-10 |
| 2021-12-31 | $64.14M 10-K · filed 2024-03-28 |
| 2021-09-30 | $62.99M 10-Q · filed 2022-11-10 |
| 2021-06-30 | -$43.17M 10-Q · filed 2022-11-10 |
| 2021-03-31 | -$27.50M 10-Q · filed 2022-08-05 |
| 2020-12-31 | -$23.56M 10-K · filed 2023-03-30 |
| 2020-09-30 | -$14.82M 10-Q · filed 2021-11-12 |
| 2020-06-30 | -$12.34M 10-Q · filed 2021-11-12 |
| 2020-03-31 | -$10.07M 10-Q · filed 2021-09-08 |
| 2019-12-31 | -$8.04M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |